In a multicenter study carried out in France, anti-VEGF-treated patients had a mean age of 66.1 years, 83.5% has type 2 diabetes, and they had a mean BCVA of 59.2 letters and a CRT of 457 μm [23]. This evidence concerns the gene VEGFA and type 2 diabetes mellitus.